The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms

Cancer Research and Treatment 2011년 43권 2호 p.75 ~ p.82

(Dahele Max) - Netherlands VU University Medical Center Department of Radiation Oncology
(Senan Suresh) - Netherlands VU University Medical Center Department of Radiation Oncology


A compelling body of non-randomized evidence has established stereotactic ablative lung radiotherapy (SABR) as a standard of care for medically inoperable patients with peripheral early-stage non-small cell lung cancer (NSCLC). This convenient outpatient therapy, which is typically delivered in 3-8 fractions, is also well tolerated by elderly and frail patients, makes efficient use of resources and is feasible using standard commercial equipment. The introduction of lung SABR into large populations has led to an increased utilization of radiotherapy, a reduction in the proportion of untreated patients and an increase in overall survival. In selected patients, the same ablative technology can now achieve durable local control of NSCLC metastases in a variety of common locations including the adrenal glands, bone, brain, and liver. At the same time as this, advances in prognostic molecular markers and targeted systemic therapies mean that there is now a subgroup of patients with stage IV NSCLC and a median survival of around 2 years. This creates opportunities for new trials that incorporate SABR and patient-specific systemic strategies. This selective mini-review focuses on the emerging role of SABR in patients with early-stage and oligometastatic NSCLC.


Non-small-cell lung carcinoma, Radiosurgery, Stereotactic body radiotherapy, Clinical trial design
원문 및 링크아웃 정보
등재저널 정보
SCI(E) MEDLINE 학술진흥재단(KCI) KoreaMed 대한의학회 회원 
주제명(Target field)
연구참여(Sample size)
질병특성(Condition Category)
연구설계(Study Design)
중재방법(Intervention Type)
중재명칭(Intervention Name)
This review article justifies the use of ablative therapies such as SABR for treating selected patients with early-stage and advanced NSCLC.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
ICD 03